20059-73-8

Usage

Uses

Used in Pharmaceutical Research:
4-[2-(Dimethylamino)ethoxy]benzylamine is used as a research compound for exploring its properties and potential applications in the development of pharmaceuticals. Its unique structure allows for investigation into its interactions with biological systems and its possible therapeutic effects.
Used in Organic Synthesis:
As a building block, 4-[2-(Dimethylamino)ethoxy]benzylamine is used in the synthesis of various organic compounds. Its presence in these compounds can influence their chemical and physical properties, making it a valuable component in the creation of new chemical entities.
Used as a Reagent in Drug Preparation:
In the pharmaceutical industry, 4-[2-(Dimethylamino)ethoxy]benzylamine is utilized as a reagent for the preparation of novel drugs. Its ability to participate in chemical reactions facilitates the development of new drug candidates with potential therapeutic benefits.
Used as an Intermediate in Chemical Production:
4-[2-(Dimethylamino)ethoxy]benzylamine also serves as an intermediate in the production of other chemicals. Its role in these processes is crucial for the synthesis of a range of chemical products, contributing to the diversity of the chemical market.
Used in Drug Development:
With its potential applications in the development of new drugs, 4-[2-(Dimethylamino)ethoxy]benzylamine is a key component in the pharmaceutical sector. Its integration into drug molecules can lead to the discovery of new therapeutic agents with improved efficacy and safety profiles.

InChI:InChI=1/C11H18N2O/c1-13(2)7-8-14-11-5-3-10(9-12)4-6-11/h3-6H,7-9,12H2,1-2H3

Upstream product

• 15182-92-0 4-(2-dimethylaminoethoxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 140-75-0 para-fluorobenzylamine 
• 149505-94-2 tert-butyl (4-hydroxybenzyl)carbamate 
• 696-60-6 4-aminomethylphenol 
• 106-44-5 p-cresol 
• 131028-55-2 [2-(4-Chloromethyl-phenoxy)-ethyl]-dimethyl-amine 
• 13468-02-5 dimethyl(2-phenoxyethyl)amine 
• 108-95-2 phenol 
• 24197-95-3 4-(2-(dimethylamino)ethoxy)-benzonitrile 

Downstream Products

• 138-56-7 Trimethobenzamide 
• 122892-84-6 4-Dimethylamino-N-[4-(2-dimethylamino-ethoxy)-benzyl]-benzamide 
• 122892-39-1 2-amino-N-<4-<2-(dimethylamiono)ethoxy>benzyl>benzamide 
• 140836-59-5 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-2-ethoxy-benzamide 
• 122892-55-1 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-4-ethoxy-benzamide 
• 122892-42-6 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-2,4-dimethoxy-benzamide 
• 122892-59-5 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-3-ethoxy-benzamide 
• 122892-60-8 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-4-propoxy-benzamide 
• 122892-62-0 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-3,4-diethoxy-benzamide 
• 122892-34-6 4-amino-5-chloro-N-<4-<2-(dimethylamino)ethoxy>benzyl>-2-methoxybenzamide 
• 122892-97-1 N-<4-<2-(dimethylamiono)ethoxy>benzyl>-3-sulfamoylbenzamide 
• 122892-38-0 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-4-fluoro-benzamide 
• 122892-73-3 2-Chloro-N-[4-(2-dimethylamino-ethoxy)-benzyl]-benzamide 
• 122892-37-9 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-4-sulfamoyl-benzamide 

Relevant academic research and scientific papers

Overcoming inaccessibility of fluorinated imines-synthesis of functionalized amines from readily available fluoroacetamides

Although imines are convenient substrates for the synthesis of functionalized amines, they may be hard to obtain, as in the case of fluorinated imines. To aid in overcoming this issue, we propose a protocol of corresponding amine synthesis from simple fluoroacetic acid-derived amides using Schwartz's reagent.

method for preparing itopride using micro flow reactor

The present invention relates to a method for preparing itopride by using a micro flow reactor, wherein the yield and the degree of purity of the itopride generated by using the micro flow reactor can be improved; thionyl chloride or oxalyl chloride can be safely used; and leakage of noxious gases, such as a sulfur dioxide gas and/or a hydrochloric acid gas can be prevented. Also, the itopride can be manufactured through a simple process without an extra separation and purification process of an intermediate product that is generated during manufacturing.

Preparation method of 4-[2-(dimethylamino)ethoxy]benzylamine

The invention provides a preparation method of 4-[2-(dimethylamino)ethoxy]benzylamine, comprising: allowing 4-hydroxybenzeneacetamide to react with 2-dimethylaminoethylchloride to obtain 4-[2-(dimethylamino)ethoxy]phenylacetamide, allowing the 4-[2-(dimethylamino)ethoxy]phenylacetamide to further react with sodium hypochlorite for Hofmann rearrangement to obtain 4-[2-(dimethylamino)ethoxy]benzylamine. The preparation method of the invention has the advantages that the synthetic route is short, raw materials are easy to obtain and cheap, the reactions are mild and convenient to perform, reaction yield is high, the quality is stable, and facilitated industrial production of the product is achieved.

Preparation method of 4-(2-dimethylaminoethoxy)benzylamine

The invention provides a preparation method of 4-(2-dimethylaminoethoxy)benzylamine. The preparation method comprises the following steps: dissolving 4-(2-dimethylaminoethoxy)benzyl bromide and urotropin in a solvent and reacting; after reacting, recycling the solvent; hydrolyzing a reaction product under an acidic condition; and adding an alkali and neutralizing to obtain the 4-(2-dimethylaminoethoxy)benzylamine. According to the preparation method provided by the invention, the raw materials have low prices and are easy to obtain; industrialization of the process is easy to realize; and the final product has high purity.

Preparation method of itopride hydrochloride

The invention relates to a preparation method of itopride hydrochloride. The preparation method includes: using 2-dimethylaminoethyl chloride hydrochloride and phenol as starting materials for reaction; subjecting the starting materials to etherification, chloromethylation, amino substitution, amidation and salifying to obtain itopride hydrochloride. Chloromethylation promoted by C/CHO is adopted, so that a step of imine reduction is omitted, solid residue generated by a reductant is eliminated, and reaction safety is improved; raw materials used in the method are low in price, sufficient in market supply and easy to purchase; reaction in each step is classic, and the preparation method is safe, easy to control and suitable for industrial production.

Quinolone amides as antitrypanosomal lead compounds with In Vivo activity

Human African trypanosomiasis (HAT) is a major tropical disease for which few drugs for treatment are available, driving the need for novel active compounds. Recently, morpholino-substituted benzyl amides of the fluoroquinolone-type antibiotics were identified to be compounds highly active against Trypanosoma brucei brucei. Since the lead compound GHQ168 was challenged by poor water solubility in previous trials, the aim of this study was to introduce structural variations to GHQ168 as well as to formulate GHQ168 with the ultimate goal to increase its aqueous solubility while maintaining its in vitro antitrypanosomal activity. The pharmacokinetic parameters of spray-dried GHQ168 and the newly synthesized compounds GHQ242 and GHQ243 in mice were characterized by elimination half-lives ranging from 1.5 to 3.5 h after intraperitoneal administration (4 mice/compound), moderate to strong human serum albumin binding for GHQ168 (80%) and GHQ243 (45%), and very high human serum albumin binding (>99%) for GHQ242. For the lead compound, GHQ168, the apparent clearance was 112 ml/h and the apparent volume of distribution was 14 liters/kg of body weight (BW). Mice infected with T. b. rhodesiense (STIB900) were treated in a stringent study scheme (2 daily applications between days 3 and 6 postinfection). Exposure to spray-dried GHQ168 in contrast to the control treatment resulted in mean survival durations of 17 versus 9 days, respectively, a difference that was statistically significant. Results that were statistically insignificantly different were obtained between the control and the GHQ242 and GHQ243 treatments. Therefore, GHQ168 was further profiled in an early-treatment scheme (2 daily applications at days 1 to 4 postinfection), and the results were compared with those obtained with a control treatment. The result was statistically significant mean survival times exceeding 32 days (end of the observation period) versus 7 days for the GHQ168 and control treatments, respectively. Spray-dried GHQ168 demonstrated exciting antitrypanosomal efficacy.

An improved process for trimethobenzamide hydrochloride

An improved process for the preparation of trimethobenzamide hydrochloride conforming to regulatory specification is reported. Specifically, a process for the preparation of trimethobenzamide hydrochloride, which is free from the associated impurities that are normally encountered during coupling of 4-(2-dimethylaminoethoxy)benzyl amine with 3,4,5-trimethoxy benzoic acid is described.

PROCESS FOR PREPARING ITOPRIDE HYDROCHLORIDE

Process for preparing itopride hydrochloride comprising: a) Reacting 4-hydroxybenzaldehyde with 2-dimethylaminoethyl chloride in the 5 presence of a weak inorganic base to obtain 4-(2-dimethylaminoethoxy)- benzaldehyde, b) Reacting 4-(2-dimethylaminoethoxy)-benzaldehyde with hydroxylamine hydrochloride in an acid environment to obtain 4-(2-dimethylaminoethoxy)- benzaldoxime hydrochloride, 10 c) Reacting of 4-(2-dimethylaminoethoxy)-benzaldoxime hydrochloride in the presence a reducing agent to 4-(2-dimethylaminoethoxy)-benzylamine, d) Reacting 4-(2-dimethylaminoethoxy)-benzylamine with veratric acid chloride in the presence of a tertiary amine to obtain itopride, e) Salifying itopride with hydrochloric acid to obtain itopride hydrochloride, 15 characterized in that the reducing agent employed in step (c) is powdered zinc.

METHOD FOR PREPARING 4-[2-(DIMETHYLAMINO)ETHOXY]BENZYLAMINE AS ITOPRIDE HYDROCLORIDE SALT MEDIATE

The present invention relates to a novel method for preparing an itopride·hydrochloride mediate of the formula 1, which is useful for digestive tract activator, and more particularly, the present invention provides with a method for preparing 4-[2-(dimethylamino)ethoxy]benzylamine of the formula 1, an itopride·hydrochloride mediate, whereby being capable of manufacturing in a high yield and lowering cost through a simple purification and a selective reaction, and the method is harmless and safe to human and environment due to not generating toxic gas. And specially, a super-high pressure hydrogenation and a reduction reaction using a metal catalyst are not carried out, therefore, it is very safe method, and also special manufacturing equipments are not needed.

METHOD FOR PRODUCING AMINOALKOXY BENZYLAMINES AND AMINOALKOXY BENZONITRILES AS INTERMEDIATES

The invention relates to methods for producing 4-[aminoalkoxy]benzylamines of general formula (I) by means of catalytic hydrogenation of 4-[aminoalkoxy]benzonitriles of general formula (II). In the compounds of general formulae (I) and (II), R1 represents C1-C8 alkylene, and R2 and R3 independently represent C1-C8 alkyl or are linked to form a ring which can also contain a heteroatom. The hydrogenation is carried out at increased pressure and increased temperatures. The invention also relates to a method for producing the intermediate (II).